Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| U01IP000475 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| All India Institute of Medical Sciences | OTHER |
| International Clinical Epidemiology Network (INCLEN) TRUST | NETWORK |
| University of Alabama at Birmingham | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Influenza viruses are significant causes of human illness and death in developed and developing countries. This study will measure the ability of influenza vaccine given to children in India to protect both the children and unimmunized persons around them from influenza. It will also determine whether the best time to immunize in a country like India that has both summer and winter outbreaks of influenza is in the fall, as is done now, or whether immunization should be in the spring to protect against influenza infections in the summer.
Although influenza vaccines are used routinely in the United States, including in young children, influenza vaccines have not seen widespread use in India. This is likely contributed to by the lack of information from India about disease burden due to influenza and because influenza vaccines have not been tested for efficacy in India. In addition, because young children are thought to be important in the spread of influenza in families, it is possible immunization of children against influenza will reduce influenza infections among older children and adults in the home. The study described here is an extension of an earlier study (ClinicalTrials.gov NCT00934245) that tested the use of immunization against influenza in the fall. The current study will administer influenza vaccine in the spring prior to the summer monsoon rains that are associated with peaks of influenza activity in parts of India. Reduction of influenza infections among the influenza immunized children and their household members will be compared to the children and household members in the control vaccine group.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Inactivated Trivalent Influenza Vaccine | Experimental | Inactivated trivalent influenza vaccine (TIV), split virion |
|
| Inactivated Polio Vaccine | Placebo Comparator | Inactivated poliovirus vaccine (IPV), trivalent |
|
| Surveillance arm | No Intervention | Those ineligible for vaccination will be enrolled for febrile acute respiratory illness (FARI) surveillance to assess indirect effects of vaccination in household members. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inactivated Trivalent Influenza Vaccine (TIV) | Biological |
| ||
| Inactivated poliovirus vaccine (IPV), trivalent |
| Measure | Description | Time Frame |
|---|---|---|
| Laboratory-confirmed influenza infection in vaccinated child | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Laboratory-confirmed influenza infection in household member of a vaccinated child. | 1 year |
Not provided
Inclusion Criteria:
Inclusion in either vaccine group (TIV or IPV) will require ages 6 months through 10 years of age.
All individuals in enrolled households will be eligible for enrollment into surveillance arm.
Exclusion Criteria:
Exclusion criteria from the vaccine groups includes known allergy to eggs, or hypersensitivity to other components of the vaccines.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Wayne Sullender, MD | University of Colorado, Denver | Principal Investigator |
| Shobha Broor, MD | All India Institute of Medical Sciences | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Comprehensive Rural Health Services Project | Ballabgarh | Haryana | India |
Not provided
| ID | Term |
|---|---|
| D007251 | Influenza, Human |
| ID | Term |
|---|---|
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D009976 | Orthomyxoviridae Infections |
| D012327 | RNA Virus Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D011054 | Poliovirus Vaccine, Inactivated |
| ID | Term |
|---|---|
| D015164 | Vaccines, Inactivated |
| D014612 | Vaccines |
| D001688 | Biological Products |
| D045424 | Complex Mixtures |
Not provided
Not provided
| Centers for Disease Control and Prevention |
| FED |
Not provided
Not provided
Not provided
Not provided
| Biological |
|
| D014777 | Virus Diseases |
| D012140 | Respiratory Tract Diseases |
| D023321 |
| Poliovirus Vaccines |
| D014765 | Viral Vaccines |